The OBR Video Center Features educational videos covering a wide range of oncology specific topics.
Dr. Sharman, Director of Research, Willamette Valley Cancer Institute, Medical Director of Hematology Research, The US Oncology Network, about the outcomes of the phase 3 study presented here at ASH investigating 1st line ibrutinib + rituximab versus FCR in younger Chronic Lymphocytic Leukemia (CLL) patients
Tags: ASH Conference CoverageLeukemia (includes ALL, AML, APL, CLL, CML, MDS, Myeloproliferative Disorders, Myelofibrosis)
Published: 06 December 2018
Noa Biran, MD, considers the role of BCMA CAR-T cells in the management of multiple myeloma
Dr. Biran, Oncology Specialist, Division of Multiple Myeloma, John Theurer Cancer Center, Part of Hackensack University Medical Center, considers the role of BCMA CAR-T cells in the management of multiple myeloma
Dr. Biran, Oncology Specialist, Division of Multiple Myeloma, John Theurer Cancer Center, Part of Hackensack University Medical Center, considers the ...
Frederick Locke, MD, offers opinion regarding off-the-shelf CAR-T cell therapies
Dr. Locke, Program Co-Leader, Immunology, Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, offers opinion regarding off-the-shelf CAR-T cell therapies
Dr. Locke, Program Co-Leader, Immunology, Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and ...
Noa Biran, MD, provides her impression of the Phase 3 ICARIA-MM study
Dr. Biran, Oncology Specialist, Division of Multiple Myeloma, John Theurer Cancer Center, Part of Hackensack University Medical Center, provides her impression of the Phase 3 ICARIA-MM study investigating isatuximab in relapsed/refractory multiple myeloma patients
Dr. Biran, Oncology Specialist, Division of Multiple Myeloma, John Theurer Cancer Center, Part of Hackensack University Medical Center, provides her ...
Timothy Illidge, MD, PhD, describes the ECHELON-2 data presented at ASH 2019
Dr. Illidge, Professor of Targeted Therapy and Oncology, Division of Cancer Sciences, The Christie Hospital, University of Manchester, describes the ECHELON-2 data presented at ASH 2019
Dr. Illidge, Professor of Targeted Therapy and Oncology, Division of Cancer Sciences, The Christie Hospital, University of Manchester, describes the ...
Noa Biran, MD, explains how JNJ-4528 differs from other CAR-T products
Dr. Biran, Oncology Specialist, Division of Multiple Myeloma, John Theurer Cancer Center, Part of Hackensack University Medical Center, explains how JNJ-4528 differs from other CAR-T products
Dr. Biran, Oncology Specialist, Division of Multiple Myeloma, John Theurer Cancer Center, Part of Hackensack University Medical Center, explains how ...
Timothy Illidge, MD, PhD, explains the purpose of targeting peripheral t-cell lymphoma
Dr. Illidge, Professor of Targeted Therapy and Oncology, Division of Cancer Sciences, The Christie Hospital, University of Manchester, explains the purpose of targeting peripheral t-cell lymphoma (PTCL)
Dr. Illidge, Professor of Targeted Therapy and Oncology, Division of Cancer Sciences, The Christie Hospital, University of Manchester, explains the ...
Noa Biran, MD, tells us about the outcomes of the CARTITUDE-1 study
Dr. Biran, Oncology Specialist, Division of Multiple Myeloma, John Theurer Cancer Center, Part of Hackensack University Medical Center, tells us about the outcomes of the CARTITUDE-1 investigating JNJ-4528 directed against BCMA in relapsed/refractory multiple myeloma
Dr. Biran, Oncology Specialist, Division of Multiple Myeloma, John Theurer Cancer Center, Part of Hackensack University Medical Center, tells us ...
Ryan Lynch, MD, on how physicians should be thinking about BTK inhibitors in the treatment of CLL
Dr. Lynch, Assistant Professor of Medicine, Hematology/Oncology, University of Washington, Seattle Cancer Care Alliance, offers opinion on how physicians should be thinking about the use of BTK inhibitors in the treatment of chronic lymphocytic leukemia (CLL)
Dr. Lynch, Assistant Professor of Medicine, Hematology/Oncology, University of Washington, Seattle Cancer Care Alliance, offers opinion on how physicians should ...
Timothy Illidge, MD, PhD, shares the the primary and secondary endpoints of the ECHELON-2 study
Dr. Illidge, Professor of Targeted Therapy and Oncology, Division of Cancer Sciences, The Christie Hospital, University of Manchester, shares the the primary and secondary endpoints of the ECHELON-2 study
Dr. Illidge, Professor of Targeted Therapy and Oncology, Division of Cancer Sciences, The Christie Hospital, University of Manchester, shares the ...
Ryan Lynch, MD, offers his impressions of the Transcend-NHL data presented at ASH 2019
Dr. Lynch, Assistant Professor of Medicine, Hematology/Oncology, University of Washington, Seattle Cancer Care Alliance, offers his impressions of the Transcend-NHL data presented at ASH 2019 investigating the use of CAR-T cell therapy in diffuse large B-cell lymphoma (DLBCL)
Dr. Lynch, Assistant Professor of Medicine, Hematology/Oncology, University of Washington, Seattle Cancer Care Alliance, offers his impressions of the Transcend-NHL ...
Ryan Lynch, MD, considers the ideal patient profile for zanubrutinib in RR-MCL
Dr. Lynch, Assistant Professor of Medicine, Hematology/Oncology, University of Washington, Seattle Cancer Care Alliance, considers the ideal patient profile for zanubrutinib in relapsed/refractory mantle cell lymphoma (RR-MCL)
Andre Goy, MD, discusses the three-year survival analysis of the ZUMA-1 study from ASH 2019
Dr. Goy, Chairman, John Theurer Cancer Center, Part of Hackensack University Medical Center, discusses the three-year survival analysis of the ZUMA-1 study investigating axicabtagene ciloleucel in diffuse large b-cell lymphoma (DLBCL) presented at ASH 2019
Frederick Locke, MD, offers opinion regarding off-the-shelf CAR-T cell therapies
Dr. Locke, Program Co-Leader, Immunology, Department of Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center and Research Institute, offers opinion regarding off-the-shelf CAR-T cell therapies
Daniel Pollyea, MD, speculates on how oral HMAs will impact the landscape in myeloid malignancies
Dr. Pollyea, Associate Professor/Clinical Director of Leukemia Services, Division of Hematology, University of Colorado School of Medicine, speculates on how the addition of oral HMAs will impact the landscape in myeloid malignancies
Ryan Lynch, MD, on whether MRD is a valid endpoint when measuring treatment efficacy in CLL
Dr. Lynch, Assistant Professor of Medicine, Hematology/Oncology, University of Washington, Seattle Cancer Care Alliance, considers whether minimal residual disease (MRD) is a valid endpoint when measuring the efficacy of treatment in chronic lymphocytic lymphoma (CLL)
Jae H. Park, MD, on incorporating CAR-T cell therapies into acute leukemia treatment algorithms
Dr. Park, Associate, Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, offers opinion on whether there is sufficient evidence to incorporate CAR-T cell therapies into acute leukemia treatment algorithms
Noa Biran, MD, considers the role of BCMA CAR-T cells in the management of multiple myeloma
Dr. Biran, Oncology Specialist, Division of Multiple Myeloma, John Theurer Cancer Center, Part of Hackensack University Medical Center, considers the role of BCMA CAR-T cells in the management of multiple myeloma
Jeffrey Sharman, MD, on the benefits of zanubrutinib as compared to other BTK inhibitors
Dr. Sharman, Director of Hematology Research, US Oncology Research, Willamette Valley Cancer Institute, on the benefits of zanubrutinib as compared to other BTK inhibitors in the management of lymphoma
Timothy Illidge, MD, PhD, on the impact of the ECHELON-2 trial data
Dr. Illidge, Professor of Targeted Therapy and Oncology, Division of Cancer Sciences, The Christie Hospital, University of Manchester, on the impact of the ECHELON-2 trial data presented at ASH 2019
Andre Goy, MD, on the TRANSCEND-CLL-004 data investigating the use of CAR-T cell therapy DLBCL
Dr. Goy, Chairman, John Theurer Cancer Center, Part of Hackensack University Medical Center, offers impressions of the TRANSCEND-CLL-004 data presented at ASH 2019 investigating the use of CAR-T cell therapy in diffuse large B-cell lymphoma (DLBCL)
Angela Dispenzieri, MD, shares the design of the TOURMALINE-AL1 study presented at ASH 2019
Dr. Dispenzieri, Hematologist, Department of Hematology, Mayo Clinic, shares the design of the TOURMALINE-AL1 study presented at ASH 2019
Ryan Lynch, MD, offers his impressions of the Transcend-NHL data presented at ASH 2019
Dr. Lynch, Assistant Professor of Medicine, Hematology/Oncology, University of Washington, Seattle Cancer Care Alliance, offers his impressions of the Transcend-NHL data presented at ASH 2019 investigating the use of CAR-T cell therapy in diffuse large B-cell lymphoma (DLBCL)
Daniel Pollyea, MD, elaborates on the evolving treatment landscape in myelodysplastic syndromes
Dr. Pollyea, Associate Professor/Clinical Director of Leukemia Services, Division of Hematology, University of Colorado School of Medicine, elaborates on how the treatment of myelodysplastic syndromes is changing as a result of clinical data presented at ASH 2019
Chaitra Ujjani, MD, tells us about Veneto-STOP study presented at ASH 2019
Dr. Ujjani, Associate Professor, Seattle Cancer Care Alliance, University of Washington, Fred Hutchinson Cancer Research Center, tells us about Veneto-STOP study presented at ASH 2019
Timothy Illidge, MD, PhD, shares the the primary and secondary endpoints of the ECHELON-2 study
Dr. Illidge, Professor of Targeted Therapy and Oncology, Division of Cancer Sciences, The Christie Hospital, University of Manchester, shares the the primary and secondary endpoints of the ECHELON-2 study
Andre Goy, MD, considers whether off-the-shelf CAR-T cell therapies are becoming a reality
Dr. Goy, Chairman, John Theurer Cancer Center, Part of Hackensack University Medical Center, considers whether off-the-shelf CAR-T cell therapies are becoming a reality
Angela Dispenzieri, MD, elaborates on the outcomes from the TOURMALINE-AL1 study
Dr. Dispenzieri, Hematologist, Department of Hematology, Mayo Clinic, elaborates on the outcomes from the TOURMALINE-AL1 study
Ryan Lynch, MD, on how physicians should be thinking about BTK inhibitors in the treatment of CLL
Dr. Lynch, Assistant Professor of Medicine, Hematology/Oncology, University of Washington, Seattle Cancer Care Alliance, offers opinion on how physicians should be thinking about the use of BTK inhibitors in the treatment of chronic lymphocytic leukemia (CLL)
Daniel Pollyea, MD, discusses the most promising emerging strategies in the management of AML
Dr. Pollyea, Associate Professor/Clinical Director of Leukemia Services, Division of Hematology, University of Colorado School of Medicine, discusses some of the novel agents, targeted therapies, and emerging strategies in the management of acute myelogenous leukemia (AML)
Chaitra Ujjani, MD, considers how physicians should be thinking about BTK inhibitors in CLL
Dr. Ujjani, Associate Professor, Seattle Cancer Care Alliance, University of Washington, Fred Hutchinson Cancer Research Center, offers opinion on how physicians should be thinking about the use of BTK inhibitors in the treatment of chronic lymphocytic leukemia (CLL)
© Caribou Publishing. All rights reserved. Reproduction in whole or in part is prohibited.